IL279606B - Anti-trem2 antibodies and methods of using them - Google Patents

Anti-trem2 antibodies and methods of using them

Info

Publication number
IL279606B
IL279606B IL279606A IL27960620A IL279606B IL 279606 B IL279606 B IL 279606B IL 279606 A IL279606 A IL 279606A IL 27960620 A IL27960620 A IL 27960620A IL 279606 B IL279606 B IL 279606B
Authority
IL
Israel
Prior art keywords
amino acid
antibody
trem2
seq
isolated antibody
Prior art date
Application number
IL279606A
Other languages
English (en)
Hebrew (he)
Other versions
IL279606A (en
Original Assignee
Alector Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55264791&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL279606(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alector Llc filed Critical Alector Llc
Publication of IL279606A publication Critical patent/IL279606A/en
Publication of IL279606B publication Critical patent/IL279606B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL279606A 2014-08-08 2015-08-08 Anti-trem2 antibodies and methods of using them IL279606B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462035336P 2014-08-08 2014-08-08
US201562135122P 2015-03-18 2015-03-18
US201562135110P 2015-03-18 2015-03-18
PCT/US2015/044396 WO2016023019A2 (en) 2014-08-08 2015-08-08 Anti-trem2 antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
IL279606A IL279606A (en) 2021-03-01
IL279606B true IL279606B (en) 2022-08-01

Family

ID=55264791

Family Applications (2)

Application Number Title Priority Date Filing Date
IL279606A IL279606B (en) 2014-08-08 2015-08-08 Anti-trem2 antibodies and methods of using them
IL250115A IL250115B (en) 2014-08-08 2017-01-15 Anti-trem2 antibodies and methods of using them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL250115A IL250115B (en) 2014-08-08 2017-01-15 Anti-trem2 antibodies and methods of using them

Country Status (11)

Country Link
US (4) US20170240631A1 (cg-RX-API-DMAC7.html)
EP (2) EP4066859A1 (cg-RX-API-DMAC7.html)
JP (4) JP6669749B2 (cg-RX-API-DMAC7.html)
CN (1) CN107106679B (cg-RX-API-DMAC7.html)
AU (2) AU2015300787A1 (cg-RX-API-DMAC7.html)
CA (2) CA2955086A1 (cg-RX-API-DMAC7.html)
EA (1) EA201790342A1 (cg-RX-API-DMAC7.html)
IL (2) IL279606B (cg-RX-API-DMAC7.html)
MX (2) MX2017001531A (cg-RX-API-DMAC7.html)
SG (2) SG11201700901SA (cg-RX-API-DMAC7.html)
WO (1) WO2016023019A2 (cg-RX-API-DMAC7.html)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2955086A1 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
US10428143B2 (en) * 2014-09-28 2019-10-01 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
WO2017058866A1 (en) * 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
CN108738323B (zh) * 2015-10-06 2023-05-26 艾利妥 抗trem2抗体及其使用方法
MA43660A (fr) 2016-01-22 2018-11-28 Adimab Llc Anticorps anti-facteur xi de coagulation
WO2017218371A1 (en) 2016-06-14 2017-12-21 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
CA3030785A1 (en) * 2016-07-22 2018-01-25 Deutsches Zentrum Fur Neurodegenerative Erkrankungen E.V. (Dzne) Trem2 cleavage modulators and uses thereof
AU2017371070B2 (en) 2016-12-09 2025-01-02 Alector Llc Anti-SIRP-alpha antibodies and methods of use thereof
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
CN108727489B (zh) * 2017-04-19 2021-02-09 广州市第八人民医院 一种单克隆抗体zk2c2及应用
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2018213316A1 (en) 2017-05-16 2018-11-22 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
WO2019014667A1 (en) 2017-07-14 2019-01-17 The Regents Of The University Of California NEW METHODS FOR PREDICTING THE RISK OF GRAFT REJECTION
TWI811229B (zh) 2017-08-03 2023-08-11 美商阿列克特有限責任公司 抗trem2抗體及其使用方法
WO2019055841A1 (en) * 2017-09-14 2019-03-21 Denali Therapeutics Inc. ANTI-TREM2 ANTIBODIES AND METHODS OF USE
KR102697811B1 (ko) * 2017-10-03 2024-08-22 프리베일 테라퓨틱스, 인크. 리소좀 장애를 위한 유전자 요법
EP3723803A4 (en) * 2017-12-12 2021-09-15 Pionyr Immunotherapeutics, Inc. ANTI-TREM2 ANTIBODIES AND RELATED PROCEDURES
US12006368B2 (en) 2017-12-19 2024-06-11 Surrozen Operating, Inc. Anti-frizzled antibodies and methods of use
AU2018393073B2 (en) 2017-12-19 2025-09-18 Surrozen Operating, Inc. Wnt surrogate molecules and uses thereof
JP7317016B2 (ja) 2017-12-19 2023-07-28 スロゼン オペレーティング， インコーポレイテッド 抗ｌｒｐ５／６抗体及び使用方法
US11440957B2 (en) * 2017-12-29 2022-09-13 Alector Llc Anti-TMEM106B antibodies and methods of use thereof
US12286478B2 (en) 2018-01-23 2025-04-29 Nextcure, Inc. B7-H4 antibodies and methods of use thereof
AR115418A1 (es) 2018-05-25 2021-01-13 Alector Llc ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS
CA3106535A1 (en) 2018-07-27 2020-01-30 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
KR20210057113A (ko) * 2018-09-11 2021-05-20 워싱턴 유니버시티 항-trem-2 작용제 항체
UY38407A (es) * 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
KR102156165B1 (ko) * 2018-10-29 2020-09-15 재단법인대구경북과학기술원 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
CA3120970A1 (en) * 2018-11-26 2020-06-04 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
WO2020121195A1 (en) * 2018-12-10 2020-06-18 Mor Research Applications Trem2 antibodies and uses thereof
WO2020123664A1 (en) * 2018-12-11 2020-06-18 Pionyr Immunotherapeutics, Inc. Methods of using anti-trem2 antibodies
CN109646668B (zh) * 2019-01-04 2019-10-18 厦门大学 一种多肽用于制备防治阿尔茨海默病药物的用途
AR118144A1 (es) * 2019-02-20 2021-09-22 Denali Therapeutics Inc Anticuerpos anti-trem2 y métodos para utilizarlos
WO2020194317A1 (en) * 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Method of treating lipid-related disorders
CN110320368A (zh) * 2019-05-30 2019-10-11 广州医科大学附属第一医院（广州呼吸中心） 基于trem2的诊断试剂盒及其在帕金森病诊断产品上的应用
EP3994159A4 (en) * 2019-07-05 2023-08-09 University of Florida Research Foundation, Incorporated METHODS OF TREATING NEUROLOGICAL DISEASES ASSOCIATED WITH THE RAN PROTEIN
JP2022540674A (ja) * 2019-07-15 2022-09-16 ブリストル－マイヤーズ スクイブ カンパニー 抗ｔｒｅｍ－１抗体およびその使用
KR20220062500A (ko) 2019-09-16 2022-05-17 서피스 온콜로지, 인크. 항-cd39 항체 조성물 및 방법
CN114667295B (zh) 2019-11-22 2024-03-29 伊莱利利公司 Trem2抗体及其用途
CN111000978B (zh) * 2019-11-22 2023-03-10 中山大学附属第五医院 Tlt-2在制备治疗结核病药物中的应用
KR20220110537A (ko) 2019-12-05 2022-08-08 알렉터 엘엘씨 항-trem2 항체 사용 방법
MX2022008582A (es) * 2020-01-13 2022-08-10 Denali Therapeutics Inc Anticuerpos anti-trem2 y metodos para utilizarlos.
IL272390A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Cancer treatment methods
WO2021174003A2 (en) * 2020-02-26 2021-09-02 Washington University Compositions and methods for reducing resistance to or enhancing immunotherapy
CR20230069A (es) * 2020-08-05 2023-08-16 Vigil Neuroscience Inc Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas de trem2
CN112526143B (zh) * 2020-12-03 2021-08-03 中山大学附属第五医院 髓系细胞触发受体2作为新型冠状病毒肺炎诊断或治疗靶点的应用
CN115141272B (zh) * 2021-01-31 2024-06-25 中南大学湘雅医院 新型冠状病毒单克隆抗体xy1及其应用
TW202330614A (zh) * 2021-11-22 2023-08-01 美商維佳神經科學有限公司 抗ｔｒｅｍ２抗體及其用途
TW202340235A (zh) 2021-12-17 2023-10-16 美商戴納立製藥公司 多肽工程、文庫及工程ｃｄ９８重鏈以及轉鐵蛋白受體結合多肽
EP4455275A1 (en) * 2021-12-22 2024-10-30 Kagoshima University Method for producing macrophages, differentiation inducing agent, differentiation induction kit, method for culturing macrophages, agent for promoting macrophage propagation, kit for promoting macrophage proliferation, method for macrophage proliferation, and macrophages
JP2025507305A (ja) * 2022-02-04 2025-03-18 ビバソル， インコーポレイテッド Ｂ７－ｈ３に結合する抗原結合タンパク質
CN119137156A (zh) * 2022-02-17 2024-12-13 阿诺基昂股份公司 用于免疫耐受的抗asgr1多肽和使用方法
CN114395034B (zh) * 2022-03-24 2022-08-05 中国科学院微生物研究所 一种高效中和新型冠状病毒的人源抗体及其应用
WO2023192282A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
US20250215077A1 (en) 2022-03-28 2025-07-03 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
JP2025529287A (ja) 2022-09-06 2025-09-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル マルファン症候群の処置のためのｔｒｅｍ－２アゴニスト
KR20250114320A (ko) * 2022-11-01 2025-07-29 비질 뉴로사이언스 인코포레이티드 항-trem2 항체 및 이의 용도
WO2024160736A1 (en) 2023-01-30 2024-08-08 Isar Bioscience Gmbh Human anti-trem2 antibody for treating neurodegenerative disorders
WO2024250809A1 (zh) * 2023-06-08 2024-12-12 成都优洛生物科技有限公司 抗trem2全人源抗体或其抗原结合片段及其应用
WO2024253424A1 (ko) * 2023-06-09 2024-12-12 재단법인대구경북과학기술원 인간 trem2 단백질에 특이적으로 결합하는 인간화 항체 및 이의 용도
WO2024262577A1 (ja) * 2023-06-21 2024-12-26 国立大学法人 鹿児島大学 ヒトマクロファージの製造方法、分化誘導剤、分化誘導キット、ヒトマクロファージの分化誘導方法、ヒトマクロファージの増殖促進剤、ヒトマクロファージの増殖促進キット、ヒトマクロファージの増殖方法及びヒトマクロファージ
WO2025015713A1 (zh) * 2023-07-19 2025-01-23 成都优洛生物科技有限公司 抗trem2人源化抗体、其抗原结合片段及其应用
WO2025032071A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025046298A2 (en) 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2025072253A1 (en) * 2023-09-25 2025-04-03 Kelonia Therapeutics, Inc. Antigen binding polypeptides
US20250101122A1 (en) 2023-09-25 2025-03-27 Kelonia Therapeutics, Inc. Antigen binding polypeptides
US12403194B2 (en) 2023-09-25 2025-09-02 Kelonia Therapeutics, Inc. Compositions for treating cancer
CN119775421B (zh) * 2023-12-21 2025-10-31 华润生物医药有限公司 抗trem2抗体及其用途

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
ATE295420T1 (de) 1992-02-06 2005-05-15 Chiron Corp Marker für krebs und biosynthetisches bindeprotein dafür
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
AU5632296A (en) 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1997011971A1 (en) 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2000000610A2 (en) 1998-06-26 2000-01-06 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
MXPA02003456A (es) 1999-10-04 2002-10-23 Medicago Inc Metodo para regular la transcripcion de genes foraneos.
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US20090081199A1 (en) 2001-03-20 2009-03-26 Bioxell S.P.A. Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
CA2342376C (en) 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
WO2003099331A1 (fr) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited Agents renforçateurs de la résistance à l'insuline
JP2004073182A (ja) 2002-05-24 2004-03-11 Takeda Chem Ind Ltd インスリン抵抗性改善剤
US20040119010A1 (en) 2002-11-01 2004-06-24 The Regents Of The University Of Colorado Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
JP2006515747A (ja) 2002-11-01 2006-06-08 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
WO2004074506A2 (en) 2003-02-13 2004-09-02 Mergen Ltd Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
MX2007008017A (es) 2004-12-31 2007-09-12 Genentech Inc Polipeptidos que se ligan a br3 y usos de los mismos.
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
AU2007225044C1 (en) 2006-03-15 2018-03-29 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
DE202006007499U1 (de) 2006-05-11 2007-01-11 Osaka University Verwendung einer Zusammensetzung, die Plexin-A1-DAP12-Interaktion inhibiert, zur Behandlung von Entzündungs-, Autoimmun- oder Knochenresorptionserkrankungen
US8093360B2 (en) 2006-09-28 2012-01-10 Elusys Therapeutics, Inc. Antibodies that bind B. anthracis exotoxin, formulations thereof, and methods of use
US7673853B2 (en) 2006-10-12 2010-03-09 Cordell Eldred Ebeling Fencing section with adjustable fencing members
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
EP2193146B1 (en) 2007-09-14 2016-05-25 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2186928A1 (en) 2008-11-14 2010-05-19 Enthone, Inc. Method for the post-treatment of metal layers
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
AU2011279073B2 (en) 2010-07-16 2016-06-09 Adimab, Llc Antibody libraries
US20130015055A1 (en) * 2011-07-11 2013-01-17 Hariharakeshava Sarpangala Hegde Dual plasma source systems and methods for reactive plasma deposition
WO2014074942A1 (en) * 2012-11-08 2014-05-15 Illumina, Inc. Risk variants of alzheimer's disease
CA2955086A1 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US10428143B2 (en) 2014-09-28 2019-10-01 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
US20170334977A1 (en) 2014-10-20 2017-11-23 The Brigham And Women's Hospital, Inc. Targeting Apolipoprotein E (APOE) in Neurologic Disease
WO2017058866A1 (en) 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
CN108738323B (zh) 2015-10-06 2023-05-26 艾利妥 抗trem2抗体及其使用方法
CA3030785A1 (en) 2016-07-22 2018-01-25 Deutsches Zentrum Fur Neurodegenerative Erkrankungen E.V. (Dzne) Trem2 cleavage modulators and uses thereof
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
TWI811229B (zh) 2017-08-03 2023-08-11 美商阿列克特有限責任公司 抗trem2抗體及其使用方法
WO2019055841A1 (en) 2017-09-14 2019-03-21 Denali Therapeutics Inc. ANTI-TREM2 ANTIBODIES AND METHODS OF USE
EP3723803A4 (en) 2017-12-12 2021-09-15 Pionyr Immunotherapeutics, Inc. ANTI-TREM2 ANTIBODIES AND RELATED PROCEDURES

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COLONNA M., TREMS IN THE IMMUNE SYSTEM AND BEYOND., 3 June 2003 (2003-06-03) *
ITO H, HAMERMAN JA., TREM-2, TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL?2, NEGATIVELY REGULATES TLR RESPONSES IN DENDRITIC CELLS., 28 September 2011 (2011-09-28) *
SUN M, ZHU M, CHEN K, NIE X, DENG Q, HAZLETT LD, WU Y, LI M, WU M, HUANG X., REM-2 PROMOTES HOST RESISTANCE AGAINST PSEUDOMONAS AERUGINOSA INFECTION BY SUPPRESSING CORNEAL INFLAMMATION VIA A PI3K/AKT SIGNALING PATHWAY, 1 May 2013 (2013-05-01) *
ZHAO Y, BHATTACHARJEE S, JONES BM, DUA P, ALEXANDROV PN, HILL JM, LUKIW WJ., REGULATION OF TREM2 EXPRESSION BY AN NF-?B-SENSITIVE MIRNA-34A, 17 April 2013 (2013-04-17) *

Also Published As

Publication number Publication date
AU2015300787A1 (en) 2017-02-02
US20170240631A1 (en) 2017-08-24
WO2016023019A2 (en) 2016-02-11
AU2021202840B2 (en) 2024-10-31
JP7730936B2 (ja) 2025-08-28
NZ766877A (en) 2024-08-30
IL250115B (en) 2021-01-31
US20190315858A1 (en) 2019-10-17
JP2020063268A (ja) 2020-04-23
IL279606A (en) 2021-03-01
IL250115A0 (en) 2017-03-30
EP4066859A1 (en) 2022-10-05
JP7326135B2 (ja) 2023-08-15
US20190010230A1 (en) 2019-01-10
AU2021202840A1 (en) 2021-06-03
HK1243006A1 (zh) 2018-07-06
JP6669749B2 (ja) 2020-03-18
CN107106679B (zh) 2022-07-26
US20230107639A1 (en) 2023-04-06
NZ729157A (en) 2024-08-30
JP2024073453A (ja) 2024-05-29
SG11201700901SA (en) 2017-03-30
EP3177322A4 (en) 2018-07-18
MX2017001531A (es) 2017-05-15
EA201790342A1 (ru) 2017-07-31
MX2023000334A (es) 2023-02-09
JP2017523814A (ja) 2017-08-24
SG10201913611QA (en) 2020-03-30
US11084875B2 (en) 2021-08-10
JP2022081543A (ja) 2022-05-31
CN107106679A (zh) 2017-08-29
EP3177322A2 (en) 2017-06-14
WO2016023019A3 (en) 2016-07-28
CA2955086A1 (en) 2016-02-11
CA3090240A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
AU2021202840B2 (en) Anti-TREM2 antibodies and methods of use thereof
US20230295297A1 (en) Anti-trem2 antibodies and methods of use thereof
US12110327B2 (en) Anti-TREM1 antibodies and methods of use thereof
JP2023179404A (ja) 抗ｃｄ３３抗体及びその使用方法
JP7525980B2 (ja) 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
HK40081580A (en) Anti-trem2 antibodies and methods of use thereof
HK40087685A (zh) 抗siglec-9抗体及其使用方法
EA042890B1 (ru) Антитела к trem2 и способы их применения
HK1243006B (en) Anti-trem2 antibodies and methods of use thereof